Browsing by Author Clarke, Philip M

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 19 of 19
Issue DateTitleAuthor(s)Citation
2013Adapting and validating diabetes simulation models across settings: Accounting for mortality differences using administrative dataHayes, Alison; Clarke, Philip M; Davis, Timothy; Davis, Wendy; School of Public Health: Public HealthAdapting and validating diabetes simulation models across settings: Accounting for mortality differences using administrative data, Journal of Diabetes and Its Complications, vol.27, 4, 2013,pp 351-356
2015Association between serum alkaline phosphatase and primary resistance to erythropoiesis stimulating agents in chronic kidney disease: a secondary analysis of the HERO trialPerkovic, Vlado; Badve, Sunil; Cass, Alan; Clarke, Philip M; Coombes, Jeff; et al, Various; Ferrari, Paolo; McDonald, Stephen; Morrish, Alicia T; Pascoe, Elaine; Pedagogos, Eugenie; Zhang, Lei; The George Institute for Global HealthAssociation between serum alkaline phosphatase and primary resistance to erythropoiesis stimulating agents in chronic kidney disease: a secondary analysis of the HERO trial, Canadian journal of kidney health and disease, vol.2, N/A, 2015,pp 1-10
2016Changes in Quality of Life Associated with Complications of Diabetes: Results from the ADVANCE StudyArima, Hisatomi; Chalmers, John; Hayes, Alison; Woodward, Mark; Clarke, Philip M; Hamet, Pavel; Poulter, Neil; The George Institute for Global Health; The George Institute for Global Health; School of Public Health: Public Health; The George Institute for Global HealthChanges in Quality of Life Associated with Complications of Diabetes: Results from the ADVANCE Study, Value in Health, vol.19, 1, 2016,pp 36-41
2016The effect of pentoxifylline on oxidative stress in chronic kidney disease patients with erythropoiesis-stimulating agent hyporesponsiveness: Sub-study of the HERO trialPerkovic, Vlado; Badve, Sunil; Cass, Alan; Clarke, Philip M; Coombes, Jeff; Dalziel, Kim; et al, Various; Ferrari, Paolo; McDonald, Stephen; Morrish, Alicia; Pascoe, Elaine; Pedagogos, Eugenie; Zhang, Lei; The George Institute for Global HealthThe effect of pentoxifylline on oxidative stress in chronic kidney disease patients with erythropoiesis-stimulating agent hyporesponsiveness: Sub-study of the HERO trial, Redox Report, vol.21, 1, 2016,pp 14-23
2015The effects of reduced copayments on discontinuation and adherence failure to statin medication in AustraliaChalmers, John; Heeley, Emma; Clarke, Philip M; Knott, Rachel J; Petrie, Dennis; The George Institute for Global Health; The George Institute for Global HealthThe effects of reduced copayments on discontinuation and adherence failure to statin medication in Australia, Health Policy, vol.119, N/A, 2015,pp 620-627
2017How Consistent is the Relationship between Improved Glucose Control and Modelled Health Outcomes for People with Type 2 Diabetes Mellitus? a Systematic ReviewLung, Thomas; Clarke, Philip M; Herman, W; Hua, X; Palmer, Andrew; Si, L; The George Institute for Global HealthHow Consistent is the Relationship between Improved Glucose Control and Modelled Health Outcomes for People with Type 2 Diabetes Mellitus? a Systematic Review, PharmacoEconomics, vol.35, 3, 2017,pp 319-329
2012How fair is Medicare? The income-related distribution of Medicare benefits with special focus on chronic care itemsCass, Alan; Chalmers, John; Heeley, Emma; Pieris, David; Clarke, Philip M; Knott, Rachel J; The George Institute for Global Health; The George Institute for Global Health; The George Institute for Global Health; The George Institute for Global HealthHow fair is Medicare? The income-related distribution of Medicare benefits with special focus on chronic care items, Medical Journal of Australia, vol.197, 11/12, 2012,pp 1-5
2015Measuring the Progressivity of the Pharmaceutical Benefits SchemeChalmers, John; Heeley, Emma; Clarke, Philip M; Knott, Rachel J; The George Institute for Global Health; The George Institute for Global HealthMeasuring the Progressivity of the Pharmaceutical Benefits Scheme, The Australian Economic Review, vol.48, 2, 2015,pp 122-132
2014A meta-analysis of the relative risk of mortality for type 1 diabetes patients compared to the general population: exploring temporal changes in relative mortalityHayes, Alison; Clarke, Philip M; Herman, William; Lei, Si; Lung, Tom; Palmer, Andrew; School of Public Health: Public HealthA meta-analysis of the relative risk of mortality for type 1 diabetes patients compared to the general population: exploring temporal changes in relative mortality, PloS One, vol.9, 11, 2014,pp 1-15
2014Optimal strategies for identifying kidney disease in diabetes: properties of screening tests, progression of renal dysfunction and impact of treatment - systematic review and modelling of progression and cost-effectivenessWong, Germaine; Clarke, Philip M; Dunger, David B.; et al, Various; Farmer, Andrew; Glasziou, Paul; Hirst, Jennifer; Lung, Tom; Neil, Andrew; Oke, Jason; Stevens, Richard; School of Public Health: Public HealthOptimal strategies for identifying kidney disease in diabetes: properties of screening tests, progression of renal dysfunction and impact of treatment - systematic review and modelling of progression and cost-effectiveness, Health Technology Assessment, vol.18, 14, 2014,pp 1-127
2015Optimal strategies for monitoring lipid levels in patients at risk or with cardiovascular disease: a systematic review with statistical and cost-effectiveness modellingIrwig, Leslie; Clarke, Philip M; Dalton, Andrew; et al, Various; Fanshawe, Thomas; Farmer, Andrew; Lung, Tom; McFadden, Emily; McLellan, Julie; Perera, Rafael; Perez, Teresa; School of Public Health: Public HealthOptimal strategies for monitoring lipid levels in patients at risk or with cardiovascular disease: a systematic review with statistical and cost-effectiveness modelling, Health Technology Assessment, vol.19, 100, 2015,pp 1-401
2014Predicting mortality in people with Type 2 diabetes mellitus after major complications: A study using Swedish National Diabetes Register dataHayes, Alison; Kelly, Patrick John; Cederholm, J; Clarke, Philip M; Eliasson, Bjorn; Gerdtham, Ulf-G; Gudbjornsdottir, Soffia; Nilsson, Peter; School of Public Health: Public Health; School of Public Health: MedicinePredicting mortality in people with Type 2 diabetes mellitus after major complications: A study using Swedish National Diabetes Register data, Diabetic Medicine, vol.31, 8, 2014,pp 954-962
2015A Randomized, Placebo-Controlled Trial of Pentoxifylline on Erythropoiesis-Stimulating Agent Hyporesponsiveness in Anemic Patients With CKD: The Handling Erythropoietin Resistance With Oxpentifylline (HERO) TrialPerkovic, Vlado; Badve, Sunil V.; Cass, Alan; Clarke, Philip M; Dalziel, Kim; et al, Various; Ferrari, Paolo; Johnson, David W; McDonald, S; Morrish, Alicia; Pascoe, Elaine; Pedagogos, Eugenie; The George Institute for Global HealthA Randomized, Placebo-Controlled Trial of Pentoxifylline on Erythropoiesis-Stimulating Agent Hyporesponsiveness in Anemic Patients With CKD: The Handling Erythropoietin Resistance With Oxpentifylline (HERO) Trial, American Journal of Kidney Diseases, vol.65, 1, 2015,pp 49-57
2016Recent trends in life expectancy for people with type 1 diabetes in SwedenLung, Thomas; Clarke, Philip M; Eliasson, Bjorn; Palmer, Andrew; Petrie, James; Rawshani, Araz; Svensson, Ann; The George Institute for Global HealthRecent trends in life expectancy for people with type 1 diabetes in Sweden, Diabetologia, vol.59, 6, 2016,pp 1167-1176
2013Simulating lifetime outcomes associated with complications for people with type 1 diabetesHayes, Alison; Clarke, Philip M; Farmer, Andrew; Lung, Tom W C; Stevens, Richard; School of Public Health: Public HealthSimulating lifetime outcomes associated with complications for people with type 1 diabetes, PharmacoEconomics, vol.31, 6, 2013,pp 509-518
2013Temporal Validation of the UKPDS Outcomes Model Using 10-Year Posttrial Monitoring DataHayes, Alison; Clarke, Philip M; Gray, Alastair; Holman, Rury R.; Leal, Jose; School of Public Health: Public HealthTemporal Validation of the UKPDS Outcomes Model Using 10-Year Posttrial Monitoring Data, Diabetes Care, vol.36, 6, 2013,pp 1541-1546
2013UKPDS Outcomes Model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82Hayes, Alison; Clarke, Philip M; Gray, Alastair; Holman, R.R.; Leal, Jose; School of Public Health: Public HealthUKPDS Outcomes Model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82, Diabetologia: clinical and experimental diabetes and metabolism, vol.56, 9, 2013,pp 1925-1933
2017Using administrative data to look at changes in the level and distribution of out-of-pocket medical expenditure: An example using Medicare data from AustraliaChalmers, John; Laba, Tracey-Lea; Clarke, Philip M; Erreygers, Guido; Hua, Xinyang; The George Institute for Global Health; The George Institute for Global HealthUsing administrative data to look at changes in the level and distribution of out-of-pocket medical expenditure: An example using Medicare data from Australia, Health Policy, vol.121, 4, 2017,pp 426-433
2016Using Classification and Regression Trees (CART) to Identify Prescribing Thresholds for Cardiovascular DiseaseChalmers, John; Heeley, Emma; Clarke, Philip M; Dalziel, Kim; Mortimer, Duncan; Schilling, Chris; The George Institute for Global Health; The George Institute for Global HealthUsing Classification and Regression Trees (CART) to Identify Prescribing Thresholds for Cardiovascular Disease, PharmacoEconomics, vol.34, 2, 2016,pp 195-205